These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22037031)

  • 1. David Urdal. Interview with Asher Mullard.
    Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic cancer vaccine survives biotech bust.
    Ledford H
    Nature; 2015 Mar; 519(7541):17-8. PubMed ID: 25739610
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 4. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 5. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 6. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Drake CG
    J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
    J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Gulley JL; Leitman SF; Dahut W; Schlom J
    J Natl Cancer Inst; 2012 Jul; 104(14):1106; author reply 1109-12. PubMed ID: 22825555
    [No Abstract]   [Full Text] [Related]  

  • 10. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

  • 11. An audience with Thomas Lönngren. Interview by Asher Mullard.
    Lönngren T
    Nat Rev Drug Discov; 2010 Dec; 9(12):912. PubMed ID: 21119726
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
    Tear S; Zarkowska T
    IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303
    [No Abstract]   [Full Text] [Related]  

  • 14. The regulator disapproves.
    Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
    [No Abstract]   [Full Text] [Related]  

  • 15. Fallout from flip-flops.
    Froese P
    Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
    [No Abstract]   [Full Text] [Related]  

  • 16. Menelas Pangalos. Interview by Asher Mullard.
    Mullard A
    Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 18. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 19. Charles Hugh-Jones. Interview by Asher Mullard.
    Hugh-Jones C
    Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.